[Ip-health] Wall Street Journal: Gilead, J&J Agree to Develop New Combination HIV Drug

Thirukumaran Balasubramaniam thiru at keionline.org
Wed Jul 13 05:45:54 PDT 2011


.

---------------------------

http://online.wsj.com/article/SB10001424052702304447804576413933613870522.html?mod=googlenews_wsj

---------------------------


	• HEALTH INDUSTRY
	• JUNE 28, 2011, 4:12 P.M. ET

Gilead, J&J Agree to Develop New Combination HIV Drug

By PETER LOFTUS

Gilead Sciences Inc. and Johnson & Johnson agreed to develop a new combination HIV drug, and are in talks to further expand their partnership on drugs for the virus.

The companies plan to develop a single-tablet combination of J&J's Prezista drug with Gilead's experimental drug cobicistat.

Prezista, which has been on the market since 2006, is a so-called protease inhibitor designed to treat HIV infection and is taken with the drug Norvir, in combination with other antiretroviral agents.

Gilead has been testing cobicistat as a "boosting agent" to enhance the effects of certain other HIV drugs. The companies plan to combine Prezista with cobicistat in a single table that can be taken once daily.

J&J will be responsible for the combination drug world-wide. Gilead will retain sole rights to manufacture, develop and commercialize cobicistat as a stand-alone product.

Gilead will receive a flat royalty as a percentage of net sales of the combination product, if it reaches market, minus the supply price of the cobicistat active ingredient contained in those net sales, said a company spokeswoman.

In addition, J&J and Gilead are negotiating terms for the development and commercialization of a single-tablet regimen combining several components: Prezista, Gilead's Emtriva and Gilead's experimental drugs GS 7340 and cobicistat.

Piper Jaffray analysts said the new deal was a modest positive for J&J as it builds a franchise in HIV medications. They said it is difficult, however, to assess the financial impact on J&J until the  negotiations on the single-tablet regimen are complete and terms are disclosed.

For Gilead, the deal further extends the company's dominance in HIV therapies, according to Lazard Capital Markets analyst Joel Sendek. Gilead's HIV drug Atripla had sales of $2.93 billion for 2010, while Truvada sales were $2.65 billion.

The moves would expand a partnership between J&J and Gilead formed in 2009. Under that deal, the companies developed a combination of Gilead's Truvada HIV drug and J&J's Edurant.

Earlier this year, Gilead resubmitted an application for Food and Drug Administration approval of the Truvada-Edurant combination, after the FDA said the initial application didn't contain sufficient information. An FDA decision is expected by mid-August. The FDA approved Edurant as a stand-alone drug in May.

Write to Peter Loftus at peter.loftus at dowjones.com


----------------------------------------


Thiru Balasubramaniam
Geneva Representative
Knowledge Ecology International (KEI)

thiru at keionline.org



Tel: +41 22 791 6727
Mobile: +41 76 508 0997









More information about the Ip-health mailing list